Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Pharma Mar S.A. (PHM) - Total Liabilities
Latest total liabilities as of December 2025: €143.25 Million EUR
Based on the latest financial reports, Pharma Mar S.A. (PHM) has total liabilities worth €143.25 Million EUR as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pharma Mar S.A. - Total Liabilities Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pharma Mar S.A. Competitors by Total Liabilities
The table below lists competitors of Pharma Mar S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunwave Communications Co Ltd
SHE:002115
|
China | CN¥1.70 Billion |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
USA | $42.57 Million |
|
Zhongshan Public Utilities Group Co Ltd
SHE:000685
|
China | CN¥17.17 Billion |
|
Outokumpu Oyj
PINK:OUTFF
|
USA | $2.30 Billion |
|
UMH Properties Inc
NYSE:UMH
|
USA | $703.12 Million |
|
Aperam PK
PINK:APEMY
|
USA | $1.96 Billion |
|
Enviri Corporation
NYSE:NVRI
|
USA | $2.39 Billion |
|
Haw Par Corporation Limited
PINK:HAWPF
|
USA | $125.21 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Pharma Mar S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharma Mar S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharma Mar S.A. (2002–2025)
The table below shows the annual total liabilities of Pharma Mar S.A. from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €143.25 Million | +1.39% |
| 2024-12-31 | €141.28 Million | -3.94% |
| 2023-12-31 | €147.08 Million | -13.63% |
| 2022-12-31 | €170.30 Million | -10.59% |
| 2021-12-31 | €190.47 Million | -16.29% |
| 2020-12-31 | €227.54 Million | +94.06% |
| 2019-12-31 | €117.25 Million | -16.37% |
| 2018-12-31 | €140.20 Million | -14.89% |
| 2017-12-31 | €164.74 Million | -4.58% |
| 2016-12-31 | €172.64 Million | +24.29% |
| 2015-12-31 | €138.90 Million | -1.71% |
| 2014-12-31 | €141.32 Million | +0.99% |
| 2013-12-31 | €139.94 Million | -13.14% |
| 2012-12-31 | €161.10 Million | -12.12% |
| 2011-12-31 | €183.31 Million | -6.45% |
| 2010-12-31 | €195.96 Million | +15.15% |
| 2009-12-31 | €170.18 Million | +7.57% |
| 2008-12-31 | €158.20 Million | +18.49% |
| 2007-12-31 | €133.51 Million | +13.89% |
| 2006-12-31 | €117.23 Million | +248.07% |
| 2005-12-31 | €33.68 Million | -6.72% |
| 2004-12-31 | €36.11 Million | -73.49% |
| 2003-12-31 | €136.20 Million | +30.29% |
| 2002-12-31 | €104.53 Million | -- |